ArticleProceedings of the National Academy of Sciences of the United States of America2017
Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models.PharmacoEconomics · 2023Pooled it
- RV144 HIV-1 vaccination impacts post-infection antibody responses.PLoS pathogens · 2020Trial
- A randomized trial to assess retention rates using mobile phone reminders versus physical contact tracing in a potential HIV vaccine efficacy population of fishing communities around Lake Victoria, Uganda.BMC infectious diseases · 2018Trial
- Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.The lancet. HIV · 2018Trial
- [Implementation of an early HIV diagnosis and treatment program in a hospital emergency department].Anales del sistema sanitario de Navarra · 2025Article
- Gay and Bisexual Men's Perceptions about a Potential HIV Vaccine within a Post-COVID-19 Era: A Qualitative Study.AIDS and behavior · 2024Article
- Human Immunodeficiency Virus Vaccine: Promise and Challenges.Infectious disease clinics of North America · 2024Review
- Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.Lancet (London, England) · 2023Article
- Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection.Annals of medicine · 2022Article
- Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Integrating diabetes, hypertension and HIV care in sub-Saharan Africa: a Delphi consensus study on international best practice.BMC health services research · 2021Article
- Article
- Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers.Microorganisms · 2020Article
- Bringing the path toward an HIV-1 vaccine into focus.PLoS pathogens · 2020Article
- A Novel Immunogen Selectively Eliciting CD8Journal of virology · 2020Article
- Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.PloS one · 2020Article
- Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Review
- Modelling microbial infection to address global health challenges.Nature microbiology · 2019Review
- Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques.PLoS pathogens · 2019Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
The HIV pandemic continues to impose enormous morbidity, mortality, and economic burdens across the globe. Simultaneously, innovations in antiretroviral therapy, diagnostic approaches, and vaccine development are providing novel tools for treatment-as-prevention and prophylaxis. We developed a mathematical model to evaluate the added benefit of an HIV vaccine in the context of goals to increase rates of diagnosis, treatment, and viral suppression in 127 countries. Under status quo interventions, we predict a median of 49 million [first and third quartiles 44M, 58M] incident cases globally from 2015 to 2035. Achieving the Joint United Nations Program on HIV/AIDS 95-95-95 target was estimated to avert 25 million [20M, 33M] of these new infections, and an additional 6.3 million [4.8M, 8.7M] reduction was projected with the 2020 introduction of a 50%-efficacy vaccine gradually scaled up to 70% coverage. This added benefit of prevention through vaccination motivates imminent and ongoing clinical trials of viable candidates to realize the goal of HIV control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.